This page covers the manufacturer layer of chronic-disease therapy: branded drugs, biologics, specialty medicines, and profitable biotech franchises that must move from diagnosis to prescription starts, refills, persistence, payer access, net price, and post-patent replacement. In the healthcare aging chain, this node sits after clinical demand and before pharmacy distribution and reimbursement gates. The current basket read is that LLY has the clearest direct volume evidence; ABBV, JNJ, MRK, AMGN, GILD, REGN, and PFE have source-backed franchise replacement or stabilization tests; VRTX and BMY remain chartable inherited rows with missing or stale local research support.
What the stack is: the drug-manufacturing and commercialization layer for chronic obesity, diabetes, immunology, oncology, HIV, cardiopulmonary, ophthalmology, rare-disease, and specialty-care medicines.
What it does in the theme: converts aging-linked disease prevalence into treated patient months, net product sales, gross margin, operating cash flow, and funding for replacement assets.
Main pieces: clinical evidence, approved labels, drug substance and fill-finish supply, sales force, specialty pharmacy access, formulary status, rebates, gross-to-net deductions, patient assistance, and lifecycle-management trials.
Where it sits: operationally between physician diagnosis and the pharmacy, benefit manager, insurer, Medicare Part D, hospital, or specialty channel that pays or controls access.
How the parent theme uses it: drug volume confirms aging demand only when starts and refills become collectible revenue after payer controls, pricing policy, and supply constraints.
Terms used later: gross-to-net is the deduction from list price for rebates, discounts, returns, and channel adjustments; LOE means loss of exclusivity; formulary access means a payer has placed the product where patients can receive coverage.
Report boundary: this node is a tactical report layer. It ranks the current value-chain basket, confirmation triggers, invalidation checks, and chart provenance. Durable research, raw source registries, and company thesis maintenance stay in the linked knowledge pages. Price and volume context comes from read-only discovery daily_ohlc through 2026-06-12.
Current Setup
Drug volume is one of the cleanest ways aging demand can reach public-market revenue, but prescriptions alone do not settle the economics. Manufacturers get paid only when a patient starts and stays on therapy, supply is available, the payer grants access, rebates and gross-to-net deductions leave enough unit growth to convert, and replacement assets grow before biosimilars or generic entry reduce the old franchise.
The strongest operating evidence is product-specific. LLY reported Q1 2026 Mounjaro and Zepbound revenue of $12.822B and cardiometabolic revenue near 80% of company revenue. ABBV has Skyrizi and Rinvoq carrying the post-Humira bridge. JNJ has oncology, TREMFYA, and neuroscience offsetting STELARA erosion. MRK is funding a Keytruda/Qlex replacement bridge through Winrevair, Ohtuvayre, and acquired assets. GILD has durable HIV cash flow, while REGN has Dupixent collaboration growth and net cash.
The main blockers are price, access, replacement timing, and source quality. CMS Medicare negotiation, Part D design, PBM formulary placement, rebates, prior authorization, loss of exclusivity, biosimilars, product concentration, and debt-funded business development can all reduce the economics even when patient demand is real. BMY and VRTX still need current local research lanes before product claims should carry full weight.
Main readDrug demand is investable when patient starts become net sales and replacement assets arrive before policy or LOE erosion.
Rank by manufacturer economics first: GLP-1 volume and cardiometabolic concentration for LLY, immunology and neuroscience replacement for ABBV, diversified drug/medtech offset for JNJ, and patent-cliff bridge quality for MRK.
Demand signalQ1 product growth is visible.
LLY, ABBV, JNJ, MRK, AMGN, GILD, REGN, and PFE all have local source-backed quarterly revenue detail.
Conversion gateAccess and net price decide cash.
Formulary placement, rebates, Medicare negotiation, supply, persistence, and gross margin decide whether prescription demand reaches EPS.
Source constraintTwo chartable rows remain evidence-light.
VRTX and BMY now have official Q1 2026 revenue sources in this report, but still lack maintained local security lanes.
Patient pooldiagnosis and starts
Access pathformulary and supply
Revenue bridgenet price and refills
Equity testcash and replacement
Fundamental claims route to the Health Care sector lane, the reimbursement-dispersion theme, and linked security lanes. Right-rail charts use live API data backed by discovery daily_ohlc; any static setup labels from the prior 2026-06-11 build are stale against 2026-06-12 local coverage and should be refreshed before use as current trading evidence.
Basket
This basket is inherited from the parent theme and ranked inside the node by source-backed chronic drug economics, net-revenue conversion, franchise replacement, financial quality, and then technical setup. Access intermediaries such as COR, MCK, CVS, and CI are important gates, but they belong in the sibling pharmacy and reimbursement nodes rather than the manufacturer-led core basket.
LLY is the clearest direct chronic-disease volume converter because Mounjaro and Zepbound are already most of the company growth bridge.
Market cap$1.010T
Next earningsNot confirmed
Latest qtr revenue$19.799B
Role in stack
LLY sells diabetes, obesity, and cardiometabolic drugs to patients whose access is controlled by payers, PBMs, Medicare design, and supply. The conversion gate is whether GLP-1 starts and refills keep translating into net sales after realized-price pressure.
Revenue mix
Q1 2026 Mounjaro plus Zepbound revenue was $12.822B, and cardiometabolic revenue was about 79.6% of company revenue.
Latest qtr revenue
Q1 2026 total revenue was $19.799B, sourced to the LLY security lane and company Q1 2026 release/10-Q. Nasdaq earnings page did not show a confirmed next date in the June 13 check.
ABBV belongs high in the node because Skyrizi and Rinvoq are the most visible post-Humira replacement engine in the local source set.
Market cap$402.35B
Next earningsNot confirmed
Latest qtr revenue$15.002B
Role in stack
ABBV sells immunology, neuroscience, oncology, and aesthetics products through payer-controlled specialty channels. Theme pressure becomes economics if Skyrizi, Rinvoq, Vraylar, and Botox offset Humira and policy pressure.
Revenue mix
Q1 2026 immunology was $7.290B, neuroscience was $2.875B, oncology was $1.631B, and Skyrizi plus Rinvoq were $6.602B.
Latest qtr revenue
Q1 2026 net revenue was $15.002B, sourced to the ABBV security lane and company Q1 2026 release. Nasdaq earnings page did not show a confirmed next date in the June 13 check.
JNJ is the diversified drug-access row because Innovative Medicine can offset STELARA erosion while MedTech adds a separate aging-demand route.
Market cap$579.82B
Next earningsNot confirmed
Latest qtr revenue$24.062B
Role in stack
JNJ sells oncology, immunology, neuroscience, and medical-technology products into payer and hospital channels. The conversion gate is whether oncology, TREMFYA, neuroscience, and procedure platforms offset STELARA pressure and litigation cash cost.
Revenue mix
Q1 2026 Innovative Medicine sales were $15.426B, or 64.1% of sales; MedTech was $8.636B.
Latest qtr revenue
Q1 2026 sales were $24.062B, sourced to the JNJ security lane and company Q1 2026 release. Nasdaq earnings page did not show a confirmed next date in the June 13 check.
MRK is the patent-cliff bridge row because current Keytruda cash flow must fund enough replacement growth before the 2028 pressure window.
Market cap$294.03B
Next earningsNot confirmed
Latest qtr revenue$16.286B
Role in stack
MRK sells oncology, vaccine, animal-health, and cardiopulmonary medicines. Demand becomes equity value if Keytruda/Qlex lifecycle management and Winrevair/Ohtuvayre launches build a bridge before Keytruda LOE.
Revenue mix
Q1 2026 pharmaceutical sales were $14.349B, Animal Health was $1.791B, and Keytruda/Qlex was about 49% of company sales.
Latest qtr revenue
Q1 2026 sales were $16.286B, sourced to the MRK security lane and company Q1 2026 release. Nasdaq earnings page did not show a confirmed next date in the June 13 check.
AMGN is the mature-biotech replacement row because growth drivers and obesity optionality must offset older franchises and balance-sheet pressure.
Market cap$191.70B
Next earningsNot confirmed
Latest qtr revenue$8.618B
Role in stack
AMGN sells general medicine, rare-disease, oncology, biosimilar, and specialty products. The conversion gate is whether growth drivers and MariTide can offset Prolia, XGEVA, Enbrel, price pressure, leverage, tax, and capex.
Revenue mix
Q1 2026 product sales were $8.218B; management's six growth drivers were about $5.6B, roughly 70% of product sales.
Latest qtr revenue
Q1 2026 revenue was $8.618B, sourced to the AMGN security lane and company Q1 2026 release. Nasdaq earnings page did not show a confirmed next date in the June 13 check.
GILD belongs in the node because chronic HIV treatment and prevention produce durable cash flow while oncology diversification remains the contested bridge.
Market cap$155.92B
Next earningsNot confirmed
Latest qtr revenue$6.960B
Role in stack
GILD sells HIV treatment and prevention products through payer and specialty channels, with oncology and cell therapy as diversification. The gate is HIV access, long-acting uptake, gross-to-net, and acquired-pipeline cash returns.
Revenue mix
Q1 2026 product sales were $6.946B; HIV was $5.030B, or 72.4% of product sales, led by Biktarvy at $3.361B.
Latest qtr revenue
Q1 2026 revenue was $6.960B, sourced to the GILD security lane and company Q1 2026 release. Nasdaq earnings page did not show a confirmed next date in the June 13 check.
REGN is the specialty-biotech row because Dupixent collaboration growth and net cash compete with EYLEA replacement risk.
Market cap$64.17B
Next earningsNot confirmed
Latest qtr revenue$3.605B
Role in stack
REGN sells and partners specialty biologics in ophthalmology, immunology, and oncology. The gate is EYLEA HD replacement, biosimilar pressure, partner-recorded Dupixent growth, pricing policy, and R&D productivity.
Revenue mix
Q1 2026 collaboration revenue was $1.900B, net product sales were $1.535B, and Dupixent global sales were $4.880B.
Latest qtr revenue
Q1 2026 revenue was $3.605B, sourced to the REGN security lane and company Q1 2026 release. Nasdaq earnings page did not show a confirmed next date in the June 13 check.
PFE is a low-expectation stabilization row where non-COVID pharma and oncology launches need to offset LOE, dividend, and leverage pressure.
Market cap$149.38B
Next earningsNot confirmed
Latest qtr revenue$14.451B
Role in stack
PFE sells vaccines, oncology, specialty, and internal-medicine products. The conversion gate is whether launches, cost realignment, and pipeline investment offset LOE, generic pressure, policy pricing, and dividend demands.
Revenue mix
Q1 2026 Biopharma revenue was $14.161B, and ex-Comirnaty/Paxlovid revenue grew 7% operationally.
Latest qtr revenue
Q1 2026 revenue was $14.451B, sourced to the PFE security lane and company Q1 2026 release. Nasdaq earnings page did not show a confirmed next date in the June 13 check.
VRTXVertex Pharmaceuticals
VRTX is kept as an inherited chartable specialty-drug row, but it should not outrank locally researched pharma names until a filed lane supports product and access claims.
Market cap$112.92B
Next earningsNot confirmed
Latest qtr revenue$2.987B
Role in stack
VRTX likely maps to rare-disease and specialty chronic therapy, but the local workspace has no filed VRTX security lane. The row is chartable and relevant, but product, payer, and margin claims need a source packet before ranking higher.
Revenue mix
Q1 2026 total CF product revenue was $2.915B, with TRIKAFTA/KAFTRIO at $2.355B, ALYFTREK at $424.4M, CASGEVY at $42.9M, and JOURNAVX at $29.0M.
Latest qtr revenue
Q1 2026 total revenue was $2.9869B, sourced to Vertex's May 4, 2026 first-quarter release. No filed local VRTX security lane exists, so broader product, payer, and margin claims remain limited.
BMYBristol Myers Squibb
BMY is retained as an inherited patent-cliff and oncology replacement row, but the local evidence is stale and should not drive the node read.
Market cap$116.66B
Next earningsNot confirmed
Latest qtr revenue$11.489B
Role in stack
BMY likely maps to oncology, hematology, immunology, and cardiovascular specialty drugs. The row remains last because no filed local security lane supports current product, access, or replacement claims.
Revenue mix
Q1 2026 Growth Portfolio revenue was $6.227B and Legacy Portfolio revenue was $5.277B; Eliquis was $4.137B and Opdivo was $2.146B.
Latest qtr revenue
Q1 2026 total revenue was $11.489B, sourced to Bristol Myers Squibb's April 30, 2026 first-quarter earnings release. No filed local BMY security lane exists, so current product and replacement claims remain limited.
Basket source note: market caps come from CompaniesMarketCap pages accessed June 13, 2026. Earnings dates were checked on Nasdaq earnings pages; the pages returned no confirmed dates, so every card is labeled Not confirmed. VRTX and BMY now use official Q1 2026 revenue releases, but both remain source-gap rows until canonical local security lanes are filed.
What Confirms Or Weakens
AreaWhat confirmsWhat weakens or invalidatesWatch next
1Node thesisDemand to sales
What confirms
Diagnosed demand converts into product-level starts, persistence, supply, net sales, margin, free cash flow, and guidance without a widening gross-to-net drag.
What weakens or invalidates
Volume grows but realized net price, rebates, supply shortages, discontinuation, or non-GAAP adjustments absorb the economics.
Watch next
Q2 product revenue
volume/price bridges
cash conversion
2Economics and accessNet-price route
What confirms
Formulary access, stable rebates, manageable Part D economics, and limited gross-to-net deterioration support net revenue.
BMY, VRTX, and NVO did not have filed local security lanes at the review timestamp. BMY and VRTX remain chartable market-data rows because the parent basket includes them; NVO remains source-only because local OHLC is missing.
AZN and INCY are sourced watch names for a future broader pharma-policy basket, not replacements for the inherited 10-row parent core in this node.
Basket Revenue, Earnings, And Market-Cap Sources
Latest-quarter revenue for LLY, ABBV, JNJ, MRK, AMGN, GILD, REGN, and PFE comes from the linked security lanes and their company Q1 2026 release or 10-Q source maps.
VRTX latest-quarter revenue comes from Vertex's May 4, 2026 first-quarter release: Q1 2026 total revenue was $2.9869B, including $2.915B of CF product revenue.
BMY latest-quarter revenue comes from Bristol Myers Squibb's April 30, 2026 first-quarter release: Q1 2026 total revenue was $11.489B, with $6.227B Growth Portfolio revenue and $5.277B Legacy Portfolio revenue.
Next earnings dates were checked on Nasdaq earnings pages for the basket on 2026-06-13. The pages showed no confirmed earnings date, so every basket card records Not confirmed.
Discovery And Chart Provenance
DuckDB source: /home/nick/projects/portfolio-manager/discovery/data/discovery.duckdb, opened read-only.
Coverage query found daily_ohlc through 2026-06-12 for LLY, ABBV, JNJ, MRK, AMGN, GILD, REGN, PFE, VRTX, and BMY; NVO had no local rows in the basket coverage query.
Discovery CLI checks performed: status LLY --json, lineage-status --ticker LLY --dataset daily_ohlc --limit 10 --json, status VRTX --json, and provider filing-index lookups for VRTX and BMY.
Weekly setup rows aggregate daily rows by calendar week using first open, maximum high, minimum low, final close, and summed volume. Indicators use 20W and 100W EMAs computed from weekly closes with full available local history.
Selected-security charts use the local report API route /api/securities/{ticker}/chart?frequency=weekly&window=3y&as_of=latest, with a three-year visible horizon, 20-week EMA, 100-week EMA, and volume subgraph. This page does not embed full OHLC arrays.
Static setup thresholds from the prior 2026-06-11 article-body table were removed. Because live API-backed chart data is newer than that setup text, refresh setup labels before using this page as current trading evidence. Horizontal overlays require assets/chart-level-rules.js registry rules.
FTC PBM interim report press release for the access-channel concentration gate: the FTC says the six largest PBMs manage nearly 95% of U.S. prescriptions and the top three processed nearly 80% of 2023 pharmacy prescriptions.
Known Gaps
BMY, VRTX, and NVO need filed security lanes before this page can make company-specific product, margin, or valuation claims with the same confidence as locally maintained rows.
NVO should be added to local discovery through the proper discovery-db-update workflow before charting or ranking it as a core GLP-1 peer.
Current-week volume is partial through 2026-06-12, so setup labels should be refreshed after the next completed market week.
Drug access and Medicare negotiation details are moving policy surfaces. Refresh CMS, payer, and company filings before using this page for a new decision cycle.